Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV.
With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.
With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.
Location: United States, California, Emeryville
Employees: 51-200
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Frazier Li... | frazierls.... |
Mentions in press and media 14
| Date | Title | Description |
| 13.08.2024 | Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates | -- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (P... |
| 03.08.2024 | GRTS Deadline: GRTS Investors Have Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit | NEW YORK, Aug. 3, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024, both dates inclusive (the &qu... |
| 26.07.2024 | Gritstone bio, Inc. Sued for Securities Law Violations - Contact The Rosen Law Firm Before August 6, 2024 to Discuss Your Rights - GRTS | NEW YORK, July 26, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024, both dates inclusive (the &q... |
| 18.06.2024 | GRTS Investors Have Opportunity to Lead Gritstone bio, Inc. Securities Fraud Lawsuit | NEW YORK, June 18, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024. Shareholders who want to serve as... |
| 05.03.2024 | Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates | - |
| 09.08.2023 | Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates | -- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE (personalized cancer vaccine [PCV]) in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); preliminary efficacy data expected in 1Q 2024 -... |
| 11.05.2023 | Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates | /EIN News/ -- -- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE (personalized vaccine in first-line metastatic microsatellite-stable colorectal cancer [MSS-CRC]) to date; 71 of 80 patients (initial target) enr... |
| 13.01.2022 | Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Color... | -- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA) reduction with extended overall survival --... |
| 25.10.2021 | Gritstone bio : Announces Presentations during Five Upcoming Investor Conferences and Events | EMERYVILLE, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone... |
| 16.09.2021 | Gritstone bio : Announces Private Placement Financing of $55.0 Million | EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies and vaccines, today announced a $55.0... |
Show more